Agency notices · Notice

Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability

Record date · Nov 20, 2026

Open official record

About this record

The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.

Record details

Federal Register document
2026-23692
Stated comment deadline
2027-01-19

Sources and related records

Source checked .